| A LATS2 and ALKBH5 positive feedback loop supports their oncogenic roles. | A LATS2 and ALKBH5 positive feedback loop supports their oncogenic roles.
Cao L, Han R, Zhao Y, Qin X, Li Q, Xiong H, Kong Y, Liu Z, Li Z, Dong F, Li T, Zhao X, Lei L, Zhao Q, Liu D, Wang B, Wu X. | 05/23/2024 |
| MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2. | MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2.
Yu H, Xu X, Zhu L, Chen S, He J., Free PMC Article | 05/20/2024 |
| RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis. | RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.
Sun Q, Lu H, Zhang W, Du Y, Liang Q, Zhang Y, Wu J, Zhong M. | 10/20/2023 |
| Mir-629 Repressed LATS2 Expression and Promoted the Proliferation of Prostate Cancer Cells. | Mir-629 Repressed LATS2 Expression and Promoted the Proliferation of Prostate Cancer Cells.
Li Y, Zeng S, Cao L. | 08/2/2023 |
| FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2. | FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.
Ma J, Wu Y, Cheng S, Yang W, Zhong L, Li Q, Fang L. | 05/3/2023 |
| The E3 ubiquitin ligase SCF (FBXW10)-mediated LATS2 degradation regulates angiogenesis and liver metastasis in colorectal cancer. | The E3 ubiquitin ligase SCF (FBXW10)-mediated LATS2 degradation regulates angiogenesis and liver metastasis in colorectal cancer.
Zhang ZY, Sun JH, Liang MJ, Wang XP, Guan J, Zhou ZQ. | 04/21/2023 |
| circPKD2 inhibits the glioma cell proliferation, invasion and glycolytic metabolism through regulating the miR-1278/LATS2 axis. | circPKD2 inhibits the glioma cell proliferation, invasion and glycolytic metabolism through regulating the miR-1278/LATS2 axis.
Liu F, Wu H, Wu G, Long J, Dai J, Wang Z. | 03/20/2023 |
| Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas. | Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas.
Kern JG, Tilston-Lunel AM, Federico A, Ning B, Mueller A, Peppler GB, Stampouloglou E, Cheng N, Johnson RL, Lenburg ME, Beane JE, Monti S, Varelas X., Free PMC Article | 12/10/2022 |
| LATS kinases and SLUG regulate the transition to advanced stage in aggressive oral cancer cells. | LATS kinases and SLUG regulate the transition to advanced stage in aggressive oral cancer cells.
Fujibayashi E, Mukai S, Torigata K, Ando Y, Uchihashi T, Nozaki M, Tanaka S, Okada M, Kogo M, Nojima H, Yabuta N., Free PMC Article | 07/30/2022 |
| Deathly triangle for pancreatic beta-cells: Hippo pathway-MTORC1-autophagy. | Deathly triangle for pancreatic β-cells: Hippo pathway-MTORC1-autophagy.
Ardestani A, Maedler K., Free PMC Article | 04/16/2022 |
| The Hippo pathway kinases LATS1 and LATS2 attenuate cellular responses to heavy metals through phosphorylating MTF1. | The Hippo pathway kinases LATS1 and LATS2 attenuate cellular responses to heavy metals through phosphorylating MTF1.
Han H, Nakaoka HJ, Hofmann L, Zhou JJ, Yu C, Zeng L, Nan J, Seo G, Vargas RE, Yang B, Qi R, Bardwell L, Fishman DA, Cho KWY, Huang L, Luo R, Warrior R, Wang W., Free PMC Article | 02/26/2022 |
| Pathological significance and prognostic role of LATS2 in prostate cancer. | Pathological significance and prognostic role of LATS2 in prostate cancer.
Matsuda T, Miyata Y, Nakamura Y, Otsubo A, Mukae Y, Harada J, Mitsunari K, Matsuo T, Ohba K, Furusato B, Sakai H., Free PMC Article | 02/26/2022 |
| Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway. | Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway.
Zhang Y, He LJ, Huang LL, Yao S, Lin N, Li P, Xu HW, Wu XW, Xu JL, Lu Y, Li YJ, Zhu SL., Free PMC Article | 02/19/2022 |
| MicroRNA miR-4709-3p targets Large Tumor Suppressor Kinase 2 (LATS2) and induces obstructive renal fibrosis through Hippo signaling. | MicroRNA miR-4709-3p targets Large Tumor Suppressor Kinase 2 (LATS2) and induces obstructive renal fibrosis through Hippo signaling.
Jiang Z, Xia W, Dai G, Zhang B, Li Y, Chen X., Free PMC Article | 02/19/2022 |
| Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer. | Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer.
Zhao C, Chen J, Liu Y, Ju S, Wang G, Wang X., Free PMC Article | 02/19/2022 |
| Apoptosis in Type 2 Diabetes: Can It Be Prevented? Hippo Pathway Prospects. | Apoptosis in Type 2 Diabetes: Can It Be Prevented? Hippo Pathway Prospects.
Kilanowska A, Ziółkowska A., Free PMC Article | 02/12/2022 |
| MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor. | MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor.
Deng X, Ye D, Hua K, Song H, Luo Q, Munankarmy A, Liu D, Zhou B, Zheng W, Zhou X, Ji C, Wang X, Yu Y, Fang L., Free PMC Article | 01/29/2022 |
| RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERalpha)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2. | RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.
Roßwag S, Sleeman JP, Thaler S., Free PMC Article | 12/25/2021 |
| LncRNA MYLK-AS1 acts as an oncogene by epigenetically silencing large tumor suppressor 2 (LATS2) in gastric cancer. | LncRNA MYLK-AS1 acts as an oncogene by epigenetically silencing large tumor suppressor 2 (LATS2) in gastric cancer.
Luo J, Xiang H., Free PMC Article | 12/4/2021 |
| A specific tRNA half, 5'tiRNA-His-GTG, responds to hypoxia via the HIF1alpha/ANG axis and promotes colorectal cancer progression by regulating LATS2. | A specific tRNA half, 5'tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2.
Tao EW, Wang HL, Cheng WY, Liu QQ, Chen YX, Gao QY., Free PMC Article | 10/23/2021 |
| Circular RNA circ_103820 suppresses lung cancer tumorigenesis by sponging miR-200b-3p to release LATS2 and SOCS6. | Circular RNA circ_103820 suppresses lung cancer tumorigenesis by sponging miR-200b-3p to release LATS2 and SOCS6.
Chi Y, Zheng W, Bao G, Wu L, He X, Gan R, Shen Y, Yin X, Jin M., Free PMC Article | 09/25/2021 |
| MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2. | MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2.
Chen X, Wang AL, Liu YY, Zhao CX, Zhou X, Liu HL, Lin MB., Free PMC Article | 09/18/2021 |
| The Hippo kinase LATS2 impairs pancreatic beta-cell survival in diabetes through the mTORC1-autophagy axis. | The Hippo kinase LATS2 impairs pancreatic β-cell survival in diabetes through the mTORC1-autophagy axis.
Yuan T, Annamalai K, Naik S, Lupse B, Geravandi S, Pal A, Dobrowolski A, Ghawali J, Ruhlandt M, Gorrepati KDD, Azizi Z, Lim DS, Maedler K, Ardestani A., Free PMC Article | 09/4/2021 |
| HTS-Compatible CometChip Enables Genetic Screening for Modulators of Apoptosis and DNA Double-Strand Break Repair. | HTS-Compatible CometChip Enables Genetic Screening for Modulators of Apoptosis and DNA Double-Strand Break Repair.
Tay IJ, Park JJH, Price AL, Engelward BP, Floyd SR. | 07/24/2021 |
| Long noncoding RNA NEAT1 suppresses hepatocyte proliferation in fulminant hepatic failure through increased recruitment of EZH2 to the LATS2 promoter region and promotion of H3K27me3 methylation. | Long noncoding RNA NEAT1 suppresses hepatocyte proliferation in fulminant hepatic failure through increased recruitment of EZH2 to the LATS2 promoter region and promotion of H3K27me3 methylation.
Wang Q, Liu L, Zhang S, Ming Y, Liu S, Cheng K, Zhao Y., Free PMC Article | 07/3/2021 |